Connect Biopharma (CNTB) Reports Positive Phase 2 COPD Add-On Results
Connect Biopharma reported preliminary topline Phase 2 data showing rademikibart cut treatment failure by 81% (p=0.0122) and new moderate-to-severe COPD exacerbations by 85% (p=0.030) through one month; hospital/ED visits for new acute exacerbations were reduced by 100% (p=0.0137).Material DetailsC…